T18515
|
Palbociclib-propargyl
|
Palbociclib-propargyl, a PROTAC ligand targeting the protein CDK6, connects to the CRBN ligand through a PEG linker to form PROTAC CP-10. CP-10 exhibits a potent DC50 value of 2.1 nM against CDK6[1].
|
T18641
|
SirReal1-O-propargyl
|
SirReal1-O-propargyl is a selective and highly potent Sirtuin 2 (Sirt2) inhibitor, with an IC50 of 2.4 μM. SirReal1-O-propargyl, the SirReal1-based moiety, binds to the cereblon ligand via a linker to form PROTAC to degrade Sirt2[1].
|
T18599
|
PROTAC BRD4-binding moiety 1
|
PROTAC BRD4-binding moiety 1 is a BRD4 ligand that binds to the cereblon ligand through a linker, enabling the formation of a PROTAC complex. This complex efficiently degrades BRD4[1].
|
T19172
|
A-1210477-piperazinyl
|
A-1210477-piperazinyl is a compound that specifically targets and binds to the protein myeloid cell leukemia 1 (MCL1). This compound is utilized in PROTAC technology, which harnesses the ability to selectively degrade target proteins.
|
T10734
|
CDK ligand for PROTAC
|
CDK ligand for PROTAC is a CDK inhibitor with antitumor activity. It has been used to design PROTAC CDK4/6 degraders.
|
T14288
|
Androstanolone acetate
|
Androstanolone acetate is a compound that functions as an androgen ligand, specifically targeting the androgen receptor (AR). It binds to the cIAP1 ligand Bestatin through a linker, resulting in the formation of PROTACs[1].
|
T13549
|
AP1867-3-(aminoethoxy)
|
AP1867-3-(aminoethoxy) is a synthetic ligand for FKBP and can be used in the synthesis of PROTAC FKBP12 F36V degrader.
|
T13915L
|
PROTAC BRD9-binding moiety 1 hydrochloride
|
PROTAC BRD9-binding moiety 1 hydrochloride binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.
|
T10716
|
CCR7 Ligand 1
|
CCR7 Ligand 1 (CCR7-Cmp2105) is an allosteric Ligand and antagonist for human CC chemokine receptor 7 (CCR7) with a Kd of 3 nM. CCR7 Ligand 1, thiadiazole-dioxide ligan, suppresses arrestin binding in response to activation by CCL19 with an IC50 of 7.3 μM
|
T17733
|
ATRA-hydroxyimino
|
ATRA-hydroxyimino, also known as CRABP-II ligand 1, is a chemical compound derived from Retinoic acid (ATRA). This compound binds to the cIAP1 ligand, specifically Bestatin, through a linker, resulting in the formation of a complex called SNIPER. The purpose of this complex is to degrade CRABP-II within IMR-32 cells[1].
|
T18593
|
GNF5-amido-Me
|
GNF5-amido-Me, the moiety based on GNF5 (ABL inhibitor),binds through a linker to the IAP ligand forming SNIPER[1].
|
T13765
|
MAK683-CH2CH2COOH
|
MAK683-CH2CH2COOH 与 EED (胚胎外胚层发育蛋白) 结合。基于MAK683-CH2CH2COOH 和 E3 泛素连接酶的 VHL 配体,设计了靶向EED 的PROTACs, PROTAC EED degrader-1 和 PROTAC EED degrader-2 。
|
T17931
|
EED226-COOH
|
EED226-COOH, derived from EED226, serves as a ligand targeting the EED protein for PROTAC applications. It attaches to a VHL ligand through a linker, culminating in the formation of UNC6852, which specifically degrades PRC2[1].
|
T18594
|
HG-7-85-01-Decyclopropane
|
Decyclopropane, also known as HG-7-85-01, is a chemical compound with ABL inhibitor properties. It binds to the IAP ligand through a linker, resulting in the formation of SNIPER [1].
|
T13696
|
FN-1501-propionic acid
|
FN-1501-propionic acid, a CDK2/9 ligand, in conjunction with a CRBN ligand, has been utilized in the design of a PROTAC CDK2/9 degrader.
|
T1835
|
Ibrutinib
|
Ibrutinib (PCI-32765) 是一种不可逆的、选择性的 Btk 抑制剂,IC50=0.5 nM,它是一种 Btk 配体,用于合成一系列 PROTAC 分子,如 P13I。P13I 作用于人 Burkitt’s 淋巴瘤 RAMOS 细胞,浓度为 10 和 100 nM 时,分别降解 73% 和 89% Btk。
|
T19301
|
DUPA
|
DUPA (N,N''-Carbonylbis[L-glutamic acid]) 是谷氨酸脲,在药物偶联中作为靶向部分,可选择靶向性地将细胞毒性药物递送到前列腺癌细胞。
|
T12551
|
PROTAC BRD4 ligand-1
|
PROTAC BRD4 ligand-1 是 PROTAC GNE-987 靶向 BRD4 蛋白的配体,也是一种 BET 的抑制剂。
|
T2066
|
Quizartinib
|
Quizartinib (AC220) 是一种具有口服活性的高选择性Ⅱ 型 FLT3酪氨酸激酶抑制剂,可诱导细胞凋亡。它抑制 Wt FLT3 和 突变型 FLT3-ITD 自磷酸化,IC50分别为 4.1 nM 和 1.1 nM。它可通过优化的 linker 与 VHL 配体连接,从而形成 PROTAC Flt3 降解剂。
|
T12186
|
Navitoclax-piperazine
|
Navitoclax-piperazine (ABT-263-piperazine) 是一种特大型 B 细胞淋巴瘤(BCL-XL)抑制剂。它和 E3 泛素连接酶的 VHL 配体可用来合成 PROTAC DT2216。
|